Anebulo Pharmaceuticals Inc 214
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.76
- Day Range
- $2.76–2.76
- 52-Week Range
- $1.71–6.90
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $71.58 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.anebulo.com
Comparables
Valuation
|
Metric
|
214
|
CRNX
|
IMVT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 12.20 | 4.43 | 6.38 |
Price/Sales | — | 1,567.62 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
214
|
CRNX
|
IMVT
|
|---|---|---|---|
Quick Ratio | 6.56 | 17.59 | 21.56 |
Current Ratio | 6.73 | 17.72 | 22.14 |
Interest Coverage | — | — | — |
Quick Ratio
214
CRNX
IMVT
Profitability
|
Metric
|
214
|
CRNX
|
IMVT
|
|---|---|---|---|
Return on Assets (Normalized) | −80.74% | −33.04% | −43.33% |
Return on Equity (Normalized) | −89.23% | −37.88% | −47.83% |
Return on Invested Capital (Normalized) | −89.23% | −39.10% | −52.69% |
Return on Assets
214
CRNX
IMVT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bqlddywh | Wsnq | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qgklmykh | Wkknjd | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fgycglsz | Njpjlky | $107.6 Bil | |
MRNA
| Moderna Inc | Byxgtxnjs | Nszxy | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Pkkmzzcxh | Rykgp | $22.2 Bil | |
ARGX
| argenx SE ADR | Krnrfxznf | Qkmf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rqwlzrc | Rkmxmg | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nlbmpgfy | Jlqbtc | $15.1 Bil | |
INCY
| Incyte Corp | Mhfkzzh | Pgbgxd | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gvtnlpzzzf | Lmgltj | $12.7 Bil |